nach oben

Zeitschrift für Rheumatologie

Erschienen in:

01.08.2015 | Leitthema

Myositiden

Was ist der aktuelle Stand?

verfasst von: Prof. Dr. K.M. Rösler, O. Scheidegger

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Dieser Beitrag gibt eine Übersicht über Einteilung, Diagnostik und Therapie der entzündlichen Muskelkrankheiten aus neurologischer Sicht. Die Myositissyndrome lassen sich grundsätzlich in 4 Gruppen einteilen: Polymyositis (PM), Dermatomyositis (DM), Einschlusskörperchenmyositis (IBM) und die in den letzten Jahren als neue Entität beschriebene nekrotisierende Myopathie (NM). Diese Krankheitsbilder unterscheiden sich in wesentlichen klinischen und histologischen Aspekten. Daneben gibt es Myositiden im Rahmen autoimmuner Systemerkrankungen („Overlap-Syndrom“). Die Diagnostik der Myositissyndrome basiert auf den klinischen Symptomen, der Bestimmung der Kreatin-Phosphokinase und Akutphasen-Parameter im Blut (CRP, BSR), der Antikörperdiagnostik, der Elektromyographie sowie dem MRT-Befund der Muskulatur. Die Muskelbiopsie ist zur Diagnosestellung unerlässlich. Qualitativ gute kontrollierte Studien zur Behandlung der myositischen Syndrome fehlen. Aufgrund empirischer Erfahrung ist am Nutzen einer immunsuppressiven Therapie bei PM, DM und NM aber nicht zu zweifeln.

Amato AA, Barohn RJ (2009) Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 80:1060–1068PubMedCrossRef

Amato AA, Greenberg SA (2013) Inflammatory myopathies. Continuum (Minneap Minn) 19:1615–1633

Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16:569–575PubMedCrossRef

Amato AA, Sivakumar K, Goyal N et al (2014) Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83:2239–2246PubMedCrossRef

András C, Ponyi A, Constantin T et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444PubMed

Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG (2015) Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. J Magn Reson Imaging 41:645–653PubMedCrossRef

Baudin PY, Azzabou N, Carlier PG, Paragios N (2012) Prior knowledge, random walks and human skeletal muscle segmentation. Med Image Comput Comput Assist Interv 15:569–576PubMed

De Bleecker JL, Lundberg IE, De Visser M (2013) 193rd ENMC International workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November – 2 December 2012, Naarden, The Netherlands. Neuromuscul Disord 23:945–951CrossRef

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMedCrossRef

10.

Brady S, Squier W, Hilton-Jones D (2013) Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 84:1240–1246PubMedCrossRef

11.

Buchthal F, Pinelli P (1953) Muscle action potentials in polymyositis. Neurology 3:424–436PubMedCrossRef

12.

Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24:45–48PubMedCrossRef

13.

Bunch TW, Worthington JW, Combs JJ et al (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92:365–369PubMedCrossRef

14.

Caramaschi P, Volpe A, Carletto A et al (2007) Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. Clin Rheumatol 26:1795–1796PubMedCrossRef

15.

Carlier PG (2014) Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: Different methodology, different information and different implications. Neuromuscul Disord 24:390–392PubMedCrossRef

16.

Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424PubMedCrossRef

17.

Cherin P, Pelletier S, Teixeira A et al (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum 46:467–474PubMedCrossRef

18.

Couderc M, Gottenberg JE, Mariette X et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 50:2283–2289PubMedCrossRef

19.

Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRef

20.

Dalakas MC, Rakocevic G, Schmidt J et al (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:1536–1544PubMedCentralPubMedCrossRef

21.

DeVere R, Bradley WG (1975) Polymyositis: its presentation, morbidity and mortality. Brain 98:637–666PubMedCrossRef

22.

Diot E, Carmier D, Marquette D et al (2011) IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 140:562–563PubMedCrossRef

23.

Dubourg O, Wanschitz J, Maisonobe T et al (2011) Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 30:103–108PubMedCentralPubMed

24.

Frikha F, Rigolet A, Behin A et al (2009) Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology 48:1166–1168PubMedCrossRef

25.

Gerami P, Walling HW, Lewis J et al (2007) A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 157:637–644PubMedCrossRef

26.

Gordon PA, Winer JB, Hoogendijk JE, Choy EHS (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev (4):CD003643 (PMID: 19821312). Cochrane Database Syst Rev 8:CD003643PubMed

27.

Grable-Esposito P, Katzberg HD, Greenberg SA et al (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41:185–190PubMed

28.

Del Grande F, Carrino JA, Del Grande M et al (2011) Magnetic resonance imaging of inflammatory myopathies. Top Magn Reson Imaging 22:39–43CrossRef

29.

Griggs RC, Askanas V, DiMauro S et al (1995) Inclusion body myositis and myopathies. Ann Neurol 38:705–713PubMedCrossRef

30.

Hayter SM, Cook MC (2012) Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 11:754–765PubMedCrossRef

31.

Hengstman GJD, Engelen BGM van, Venrooij WJ van (2004) Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 16:692–699PubMed

32.

Janiczek RL, Gambarota G, Sinclair CDJ et al (2011) Simultaneous T₂ and lipid quantitation using IDEAL-CPMG. Magn Reson Med 66:1293–1302PubMedCrossRef

33.

Jordan B, Hanisch F, Zierz S (2011) Myositiden. Nervenheilkunde 10:776–786

34.

Kagan LJ (1977) Myoglobinemia in inflammatory myopathies. JAMA 237:1448–1452PubMedCrossRef

35.

Lambert EH, Sayre GP, Eaton LM (1954) Electrical activity of muscle in polymyositis. Trans Am Neurol Assoc 13:64–69PubMed

36.

Love LA, Leff RL, Fraser DD et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374

37.

Mammen AL, Chung T, Christopher-Stine L et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63:713–721PubMedCentralPubMedCrossRef

38.

Marie I, Menard J-F, Hatron PY et al (2010) Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken) 62:1748–1755CrossRef

39.

Mechler F (1974) Changing electromyographic findings during the chronic course of polymyositis. J Neurol Sci 23:237–242PubMedCrossRef

40.

Mercuri E, Pichiecchio A, Allsop J et al (2007) Muscle MRI in inherited neuromuscular disorders: Past, present, and future. J Magn Reson Imaging 25:433–440PubMedCrossRef

41.

Van der Meulen MFG, Bronner IM, Hoogendijk JE et al (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316–321CrossRef

42.

Miller J, Walsh Y, Saminaden S et al (2002) Randomised double-blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 199:S53

43.

Mohassel P, Mammen AL (2013) Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 48:477–483PubMedCrossRef

44.

Needham M, Fabian V, Knezevic W et al (2007) Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 17:194–200PubMedCrossRef

45.

Nirkko AC, Rösler KM, Hess CW (1995) Sensitivity and specificity of needle electromyography: a prospective study comparing automated interference pattern analysis with single motor unit potential analysis. Electroencephalogr Clin Neurophysiol 97:1–10PubMedCrossRef

46.

Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324PubMedCentralPubMedCrossRef

47.

Payan J (1984) Electromyography in polymyositis and some related disorders. Clin Rheum Dis 10:75–83PubMed

48.

Ramanan AV, Campbell-Webster N, Ota S et al (2005) The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 52:3570–3578PubMedCrossRef

49.

Riddoch D, Morgan-Hughes JA (1975) Prognosis in adult polymyositis. J Neurol Sci 26:71–80PubMedCrossRef

50.

Rose MR (2013) 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 23:1044–1055PubMedCrossRef

51.

Rowin J, Amato AA, Deisher N et al (2006) Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66:1245–1247PubMedCrossRef

52.

Schmidt J (2009) Pathogenese der Einschlusskörperchenmyositis: Stellenwert der Entzündung und Bedeutung für Therapiestrategien. Aktuelle Neurol 36:121–125CrossRef

53.

Schmidt J, Vorgerd M (2011) Therapiestandard bei Myositiden und Muskeldystrophien. Nervenarzt 82:723–732PubMedCrossRef

54.

Schoser B (2009) Inflammatory myopathies. Z Rheumatol 68:665–675 (quiz 676–677)PubMedCrossRef

55.

Sem M, Molber Ø, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome – a retrospective case series. Rheumatology 48:968–971PubMedCrossRef

56.

Seshadri R, Feldman BM, Ilowite N et al (2008) The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 59:989–995PubMedCentralPubMedCrossRef

57.

Streib EW, Wilbourn AJ, Mitsumoto H (1979) Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis. Muscle Nerve 2:14–18PubMedCrossRef

58.

Thibaud J-L, Azzabou N, Barthelemy I et al (2012) Comprehensive longitudinal characterization of canine muscular dystrophy by serial NMR imaging of GRMD dogs. Neuromuscul Disord 22(Suppl 2):S85–S99PubMedCrossRef

59.

Tournadre A (2014) Prise en charge thérapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies nécrosantes auto-immunes. Rev Med Interne 35:466–471PubMedCrossRef

60.

Troyanov Y, Targoff IN, Tremblay J-L et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84:231–249

61.

Uchino M, Yamashita S, Uchino K et al (2012) Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy. Eur Neurol 68:117–121PubMedCrossRef

62.

Uncini A, Lange DJ, Lovelace RE et al (1990) Long-duration polyphasic motor unit potentials in myopathies: a quantitative study with pathological correlation. Muscle Nerve 13:263–267PubMedCrossRef

63.

Vencovský J, Jarosová K, Machácek S et al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102PubMedCrossRef

64.

Villalba L, Hicks JE, Adams EM et al (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399PubMedCrossRef

65.

Van de Vlekkert J, Hoogendijk JE, Haan RJ de et al (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 20:382–389CrossRef

66.

Vlekkert J Van De, Maas M, Hoogendijk JE et al (2015) Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve 51:253–258CrossRef

67.

Werner JL, Christopher-Stine L, Ghazarian SR et al (2012) Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64:4087–4093PubMedCentralPubMedCrossRef

Titel: Myositiden
Was ist der aktuelle Stand?
verfasst von: Prof. Dr. K.M. Rösler
O. Scheidegger
Publikationsdatum: 01.08.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 6/2015
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-014-1547-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Myositiden

Was ist der aktuelle Stand?

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Myalgie und Myopathie

Subclinical atherosclerosis in systemic lupus erythematosus patients and its relationship to disease activity and damage indices

Immunologisches Gedächtnis des Knochenmarks

Treat to Participation

Effectiveness of aquatic exercise for treatment of knee osteoarthritis

Adulter Morbus Still mit Kleingefäßvaskulitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin